PERSPECTA

News from every angle

← Back to headlines

Elicio Stock Falls After Pancreatic Cancer Drug Fails Phase 2 Trial

Elicio Therapeutics' stock experienced a significant drop following the release of disappointing phase 2 clinical trial data for its pancreatic cancer treatment.

15 Jun, 15:24 — 15 Jun, 15:24
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed15h ago

Elicio nosedives on phase 2 data for pancreatic cancer asset

Read full article →

Related Stories

Extreme Training: What Heat Training Does to the Body

just now

Dutch 'Petrified Neighborhoods' Face Increasing Heat, Affecting Nearly a Million

41m ago

Body Changes After Weight Loss: Addressing Skin Sagging

41m ago

Behavioral Addiction: When Actions Become a Loop of Dependence

41m ago